Approval of YESAFILI™ Marks a New Era for Biocon Biologics
Biocon Biologics Ltd., a dynamic global player in the biosimilars arena, is celebrating a landmark achievement. With the recent approval from Health Canada for YESAFILI™ (aflibercept), they are poised to transform the treatment landscape for various serious retinal diseases. This groundbreaking development not only underscores Biocon's commitment to innovative healthcare solutions but also positions YESAFILI as the first biosimilar to EYLEA® approved in Canada.
A Comprehensive Approach to Healthcare
Health Canada granted a Notice of Compliance for YESAFILI as of June 26, 2025, and plans for its launch in the Canadian market are set for July 4, 2025. This approval was backed by an extensive suite of analytical, clinical, and nonclinical data that demonstrated YESAFILI's close resemblance to the reference product, EYLEA, without any significant differences in quality, safety, and efficacy.
Indication for YESAFILI™
YESAFILI is specifically indicated for treating:
- Neovascular (wet) age-related macular degeneration (AMD)
- Visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO)
- Visual impairment caused by macular edema secondary to branch retinal vein occlusion (BRVO)
- Diabetic macular edema (DME)
- Myopic choroidal neovascularization (myopic CNV)
Celebrating Innovation and Commitment
As Shreehas Tambe, CEO of Biocon Biologics, emphasized, the approval of YESAFILI is a proud moment that reflects their dedication to driving innovation and expanding access to affordable biologic therapies. The upcoming launch in Canada represents a significant milestone, marking YESAFILI as the tenth biosimilar from Biocon's wide portfolio to hit the global market.
Advancing Patient Care
Ramy Ayad, who leads the operations in Canada, expressed optimism about the approval. He noted that YESAFILI will significantly elevate treatment options available to Canadian patients suffering from serious retinal diseases, enabling healthcare providers access to a high-quality and cost-effective biosimilar.
Detailed Insights into YESAFILI™
This biosimilar has been thoroughly examined in clinical studies, including a pivotal Phase 3 INSIGHT Study comparing YESAFILI with EYLEA in patients with Diabetic Macular Edema. Results indicate that there were no clinically meaningful differences observed among the two therapies regarding pharmacokinetics, safety, and efficacy.
Safety Precautions for YESAFILI™
As with any medication, specific warnings and precautions accompany the use of YESAFILI. Healthcare professionals will provide detailed instructions on its administration and potential temporary effects patients might experience:
- Patients must not undergo treatment with YESAFILI if they have ocular infections or active intraocular inflammation.
- Visual disturbances may occur temporarily post-injection; therefore, patients should refrain from driving until their vision stabilizes.
- Comprehensive safety monitoring is essential, as reactions can range from mild to more severe conditions like endophthalmitis or retinal detachment.
Biocon Biologics: Transforming Lives through Innovation
Biocon Biologics Limited prides itself on being a fully integrated biosimilars company committed to enhancing healthcare access globally. With a presence across 120+ countries, the company has successfully commercialized nine biosimilars and has a robust pipeline of 20 additional assets across various therapeutic areas, including oncology, ophthalmology, and immunology.
Emphasizing sustainability, Biocon's initiatives aim to address broader healthcare goals while delivering advanced, affordable therapies to millions of patients worldwide.
Frequently Asked Questions
What is YESAFILI™?
YESAFILI™ (aflibercept) is a biosimilar approved for treating various retinal diseases, including wet AMD and diabetic macular edema.
When will YESAFILI™ be available in Canada?
YESAFILI is expected to be launched in Canada on July 4, 2025.
How does YESAFILI compare to EYLEA®?
YESAFILI has been proven to be highly similar to EYLEA with no clinically meaningful differences in terms of safety and efficacy.
What are the main uses of YESAFILI™?
It is indicated for treating neovascular AMD, CRVO, BRVO, diabetic macular edema, and myopic CNV.
Is YESAFILI safe for all patients?
YESAFILI is contraindicated in patients with specific conditions such as ocular infections or hypersensitivity to aflibercept.
